NO20063556L - HIV gp41 HR2-avledede syntetiske peptider og deres anvendelse ved behandling av human mangel pa immunitet mot virus - Google Patents

HIV gp41 HR2-avledede syntetiske peptider og deres anvendelse ved behandling av human mangel pa immunitet mot virus

Info

Publication number
NO20063556L
NO20063556L NO20063556A NO20063556A NO20063556L NO 20063556 L NO20063556 L NO 20063556L NO 20063556 A NO20063556 A NO 20063556A NO 20063556 A NO20063556 A NO 20063556A NO 20063556 L NO20063556 L NO 20063556L
Authority
NO
Norway
Prior art keywords
hiv
synthetic peptides
amino acid
treating human
synthetic
Prior art date
Application number
NO20063556A
Other languages
English (en)
Norwegian (no)
Inventor
Mary K Delmedico
John Dwyer
Original Assignee
Trimeris Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trimeris Inc filed Critical Trimeris Inc
Publication of NO20063556L publication Critical patent/NO20063556L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/24—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a MBP (maltose binding protein)-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
NO20063556A 2004-01-07 2006-08-04 HIV gp41 HR2-avledede syntetiske peptider og deres anvendelse ved behandling av human mangel pa immunitet mot virus NO20063556L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53481004P 2004-01-07 2004-01-07
PCT/US2004/042918 WO2005067960A1 (en) 2004-01-07 2004-12-21 HIV gp41 HR2-DERIVED SYNTHETIC PEPTIDES, AND THEIR USE IN THERAPY TO INHIBIT TRANSMISSION OF HUMAN IMMUNODEFICIENCY VIRUS

Publications (1)

Publication Number Publication Date
NO20063556L true NO20063556L (no) 2006-10-06

Family

ID=34794319

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20063556A NO20063556L (no) 2004-01-07 2006-08-04 HIV gp41 HR2-avledede syntetiske peptider og deres anvendelse ved behandling av human mangel pa immunitet mot virus

Country Status (12)

Country Link
US (1) US20060247416A1 (ja)
EP (1) EP1708734A4 (ja)
JP (1) JP2007517522A (ja)
KR (1) KR20070006708A (ja)
CN (1) CN1901931A (ja)
AU (1) AU2004313242A1 (ja)
BR (1) BRPI0418304A (ja)
CA (1) CA2551082A1 (ja)
IL (1) IL176721A0 (ja)
NO (1) NO20063556L (ja)
RU (1) RU2006128593A (ja)
WO (1) WO2005067960A1 (ja)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200722436A (en) * 2005-10-21 2007-06-16 Hoffmann La Roche A peptide-immunoglobulin-conjugate
CN1793170A (zh) * 2005-12-14 2006-06-28 中国人民解放军军事医学科学院生物工程研究所 抑制hiv病毒融合的多肽及其用途
DK1989220T3 (da) 2006-02-02 2012-04-02 Trimeris Inc HIV-fusionsinhibitorpeptider med forbedrede biologiske egenskaber
JP2008029239A (ja) * 2006-07-27 2008-02-14 Gekkeikan Sake Co Ltd Ｎ３６結合ペプチドの製造方法
AU2007286451A1 (en) 2006-08-17 2008-02-21 F. Hoffmann-La Roche Ag A conjugate of an antibody against CCR5 and an antifusogenic peptide
TW200817438A (en) 2006-08-17 2008-04-16 Hoffmann La Roche A conjugate of an antibody against CCR5 and an antifusogenic peptide
US20090143288A1 (en) * 2007-03-13 2009-06-04 Roche Palo Alto Llc Peptide-complement conjugates
CN101678125A (zh) * 2007-04-03 2010-03-24 特里梅里斯公司 用于递送抗病毒肽治疗剂的新制剂
CL2008002092A1 (es) 2007-07-20 2009-05-29 Hoffmann La Roche Conjugado que contiene dos o mas peptidos antifusogenicos y un anticuerpo anti-cd-4; metodo de produccion; composicion farmaceutica que lo comprende; polipeptidos antifusogenicos y uso del conjugado para tratar infecciones viricas.
JP2010540528A (ja) * 2007-09-25 2010-12-24 トリメリス，インコーポレーテッド 治療的抗ウイルス性ペプチドの新規合成方法
JP5788178B2 (ja) 2008-01-23 2015-09-30 ダナ ファーバー キャンサー インスティテュート インコーポレイテッド ウィルス感染症の治療のための組成物及び方法
WO2009155789A1 (zh) * 2008-06-25 2009-12-30 中国人民解放军军事医学科学院毒物药物研究所 抑制hiv感染的多肽及其衍生物
WO2010089129A1 (en) 2009-02-06 2010-08-12 Cormus Srl Inhibitors of viral fusion and uses thereof
US8293100B2 (en) 2009-03-13 2012-10-23 Terrasep, Llc Methods and apparatus for centrifugal liquid chromatography
WO2010148335A2 (en) * 2009-06-18 2010-12-23 Dana Farber Cancer Institute, Inc. Structured viral peptide compositions and methods of use
WO2012020108A2 (en) 2010-08-11 2012-02-16 Cormus Srl Multimeric inhibitors of viral fusion and uses thereof
BR112013002292A2 (pt) 2010-09-14 2016-06-14 Hoffmann La Roche polipeptídeo du fusão, complexo de proteína, uso e kit
US20140357577A1 (en) * 2011-12-19 2014-12-04 Janssen R&D Limited HIV Membrane Fusion Inhibitors
CN110404051A (zh) * 2019-03-27 2019-11-05 汪炬 用于治疗脱发的短肽、药物及其应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4016273A (en) * 1975-07-16 1977-04-05 American Cyanamid Company Sustained release forms of certain oxazepines for parenteral administration
JPS55154991A (en) * 1979-05-23 1980-12-02 Hisamitsu Pharmaceut Co Inc Beta-d-fructopyranoside derivative
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4530840A (en) * 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US5411951A (en) * 1984-10-04 1995-05-02 Monsanto Company Prolonged release of biologically active somatotropin
US4629783A (en) * 1985-04-29 1986-12-16 Genetic Systems Corporation Synthetic antigen for the detection of AIDS-related disease
US5234520A (en) * 1987-03-20 1993-08-10 Morgan Adhesives Co. Method of making an adhesive construction
US4938763B1 (en) * 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5462863A (en) * 1989-02-09 1995-10-31 Development Center For Biotechnology Isolation of Hepatitis B surface antigen from transformed yeast cells
US5776963A (en) * 1989-05-19 1998-07-07 Hoechst Marion Roussel, Inc. 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility
AU2791792A (en) * 1991-10-04 1993-05-03 Robert H. Cornett Approaching emergency vehicle warning system
ES2139017T3 (es) * 1992-07-20 2000-02-01 Univ Duke Compuestos que inhiben la replicacion del vih.
US5728553A (en) * 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
JP3698721B2 (ja) * 1993-02-23 2005-09-21 ジェネンテク・インコーポレイテッド 有機溶媒を用いて処理したポリペプチドの賦形剤安定化
US5464933A (en) * 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
US6479055B1 (en) * 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
GB9404270D0 (en) * 1994-03-05 1994-04-20 Delta Biotechnology Ltd Yeast strains and modified albumins
US6004549A (en) * 1994-12-14 1999-12-21 Schering Corporation Crystalline protein controlled release compositions
US6475491B1 (en) * 1995-06-07 2002-11-05 Trimeris, Inc. Treatment of HIV and other viral infections using combinatorial therapy
US5747058A (en) * 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
US6413536B1 (en) * 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
US20020064546A1 (en) * 1996-09-13 2002-05-30 J. Milton Harris Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor
US6191107B1 (en) * 1997-09-26 2001-02-20 Takeda Chemical Industries, Ltd. Complex of human growth hormone and zinc
WO1999033491A1 (fr) * 1997-12-26 1999-07-08 Yamanouchi Pharmaceutical Co., Ltd. Compositions medicinales a liberation prolongee
US6281331B1 (en) * 1998-03-23 2001-08-28 Trimeris, Inc. Methods and compositions for peptide synthesis
US6258782B1 (en) * 1998-05-20 2001-07-10 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US6656906B1 (en) * 1998-05-20 2003-12-02 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US6143314A (en) * 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
US6565874B1 (en) * 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US6541020B1 (en) * 1999-07-09 2003-04-01 Trimeris, Inc. Methods and compositions for administration of therapeutic reagents
IL152360A0 (en) * 2000-04-19 2003-05-29 Genentech Inc Sustained release formulations
PT1397155E (pt) * 2001-06-21 2015-12-07 Genentech Inc Formulação de libertação sustentada
CN1100564C (zh) * 2001-08-29 2003-02-05 周根发 用于治疗hiv感染的药物、其组合物及其用途
US7045552B2 (en) * 2002-09-27 2006-05-16 Trimeris, Inc. Pharmaceutical composition for improved administration of HIV gp41-derived peptides, and its use in therapy
WO2005089805A2 (en) * 2004-03-15 2005-09-29 Nektar Therapeutics Al, Corporation Polymer-based compositions and conjugates of hiv entry inhibitors

Also Published As

Publication number Publication date
RU2006128593A (ru) 2008-02-20
KR20070006708A (ko) 2007-01-11
AU2004313242A1 (en) 2005-07-28
US20060247416A1 (en) 2006-11-02
IL176721A0 (en) 2006-10-31
EP1708734A4 (en) 2009-06-17
JP2007517522A (ja) 2007-07-05
CN1901931A (zh) 2007-01-24
BRPI0418304A (pt) 2007-05-02
CA2551082A1 (en) 2005-07-28
EP1708734A1 (en) 2006-10-11
WO2005067960A1 (en) 2005-07-28

Similar Documents

Publication Publication Date Title
NO20063556L (no) HIV gp41 HR2-avledede syntetiske peptider og deres anvendelse ved behandling av human mangel pa immunitet mot virus
RU2012157303A (ru) Адаптированная рекомбиназа для рекомбинации асимметричных участков-мишеней во множестве штаммов ретровирусов
RU2011151877A (ru) Пептиды, проникающие в клетку
BRPI0815578B8 (pt) peptídeos, agentes farmacêuticos compreendendo os mesmos, métodos in vitro para induzir uma célula apresentadora de antígeno, usos dos referidos peptídeos, e vacina
BRPI0412845A (pt) herpes-vìrus, uso de um vìrus, composição farmacêutica, e, método de tratamento de um tumor em um indivìduo em necessidade do mesmo
WO2010135491A3 (en) Fibroblast growth factor mutants having improved functional half-life and methods of their use
WO2008005880A3 (en) Antibodies for norovirus
ATE293169T1 (de) Latency associated peptide von tgf-beta um pharmazeutisch aktive proteine latent zu machen
DE60114018D1 (de) Von zellen präsentierte peptide
WO2009087110A8 (en) Secretable hiv entry inhibitory peptides for therapy of hiv infection
Pilkis et al. Active site sequence of hepatic fructose-2, 6-bisphosphatase. Homology in primary structure with phosphoglycerate mutase.
ES2673972T3 (es) Formas solubles de la glicoproteína G de los virus hendra y nipah
GB2429711A (en) Heart and skeletal muscle inflammation (HSMI) virus
EP1842911A4 (en) HLA BINDING PEPTIDES, FOR THOSE CODING DNA FRAGMENTS AND RECOMBINANT VECTORS
WO2004070002A3 (en) Cell lines and host nucleic acid sequences related to infectious disease
WO1994026903A3 (en) Human influenza virus peptides binding hla-i molecule
EP1757687A4 (en) HLA BINDING PEPTIDE, PRE-STEP, DNA DOMAGING AND RECOMBINANT VECTOR
ATE283035T1 (de) Integriertende protein-dna cochleateformulierungen und verfahren zur transformation von zellen
ATE411812T1 (de) Peptide zur behandlung von infektionen mit dem herpes-virus
WO2004024756A2 (en) Orthopoxvirus antigens and use thereof
JP2016524594A (ja) 遺伝子移入促進因子プロトランスズジン（Ｐｒｏｔｒａｎｓｄｕｚｉｎ）Ｂ
EP1801211A4 (en) BINDING PEPTIDE HLA MOLECULE, DNA FRAGMENT ENCODING SAME, AND RECOMBINANT VECTOR
WO2006014234A3 (en) Novel recombinant poxvirus composition and uses thereof
GB201019437D0 (en) Methods and molecules for immunotherapy
WO2007127290A3 (en) Method for producing viral vaccine and therapeutic peptide antigens

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application